A Plus Biotechnology Co (TPE:6918) Total Current Liabilities: NT$198.1 Mil (As of Dec. 2025)


TPE:6918 A Plus Biotechnology Co Ltd TPE:6918
71 GF Score
Price NT$74.20
GF Value NT$87.15
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is A Plus Biotechnology Co Total Current Liabilities?

A Plus Biotechnology Co TPE:6918 -1.59% 71 Total Current Liabilities is NT$198.1 Mil as of Dec. 2025. GuruFocus rates TPE:6918 with a GF Score™ of 71/100 and a GF Value™ of NT$87.15 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. A Plus Biotechnology Co's total current liabilities for the quarter that ended in Dec. 2025 was NT$198.1

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

A Plus Biotechnology Co Total Current Liabilities Related Terms

A Plus Biotechnology Co Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for A Plus Biotechnology Co's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A Plus Biotechnology Co Total Current Liabilities Chart

A Plus Biotechnology Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Current Liabilities
Get a 7-Day Free Trial 203.35 173.63 142.83 163.31 198.13

A Plus Biotechnology Co Quarterly Data
Dec19 Dec20 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 163.31 289.13 168.71 187.69 198.13
TPE:6918
71GF Score
A Plus Biotechnology Co Ltd TPE:6918
Total Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

A Plus Biotechnology Co Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

A Plus Biotechnology Co's Total Current Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=160.603+13.157
+Other Current Liabilities+Current Deferred Liabilities
=24.373+0
=198.1

A Plus Biotechnology Co's Total Current Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=160.603+13.157
+Other Current Liabilities+Current Deferred Liabilities
=24.373+0
=198.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of NT$198.1 Mil mean?
A Plus Biotechnology Co (TPE:6918) has a Total Current Liabilities of NT$198.1 Mil as of Dec. 2025. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for A Plus Biotechnology Co and its competitors.
Is A Plus Biotechnology Co's Total Current Liabilities too high?
A Plus Biotechnology Co's current Total Current Liabilities is NT$198.1 Mil. Overall, A Plus Biotechnology Co has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does A Plus Biotechnology Co's Total Current Liabilities compare to ABT and SYK?
A Plus Biotechnology Co's Total Current Liabilities of NT$198.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Medical Devices & Instruments company?
A good Total Current Liabilities depends on the Medical Devices & Instruments industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for A Plus Biotechnology Co and its competitors. A Plus Biotechnology Co's current Total Current Liabilities is NT$198.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is A Plus Biotechnology Co stock overvalued right now?
Based on GuruFocus' analysis, A Plus Biotechnology Co (TPE:6918) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$87.15, compared to a current price of NT$74.20 — trading 14.9% below its estimated fair value. The current Total Current Liabilities is NT$198.1 Mil. A Plus Biotechnology Co's overall GF Score™ is 71/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For A Plus Biotechnology Co (TPE:6918), the current Total Current Liabilities is NT$198.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is A Plus Biotechnology Co (TPE:6918) Overvalued in 2026?

Based on GuruFocus' analysis, A Plus Biotechnology Co stock appears to be undervalued. The current stock price of NT$74.20 is trading 14.9% below its estimated GF Value™ of NT$87.15. GuruFocus considers A Plus Biotechnology Co to be Modestly Undervalued.

Key valuation signals for TPE:6918:

  • Total Current Liabilities: NT$198.1 Mil
  • GF Value™: NT$87.15 vs. price of NT$74.20 (14.9% below fair value)
  • GF Score™: 71/100 with 3 warning signs

No single metric tells the full story. See the TPE:6918 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

A Plus Biotechnology Co Business Description

Address No. 21, Qiaohe Road, 3rd Floor, Zhonghe District, New Taipei City, TWN
A Plus Biotechnology Co Ltd provides orthopedic implants and engages in the manufacturing and wholesale of medical devices such as bone material. The company's products include Chest, Shoulder, Spine, Elbow, Wrist & Hand, Pelvic & Hip, Knee, Foot & Ankle, Osteotomy, Pediatric & ESF, and Biologics. The company currently has operating segments in Taiwan and China, with the majority of revenue coming from Taiwan.
71GF Score

Get the complete analysis for TPE:6918

Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$74.20
Price
NT$87.15
GF Value